Mikirova NA, Jackson JA, Hunninghake R, Kenyon J, Chan KW, Swindlehurst CA, Minev B, Patel AN, Murphy MP, Smith L, Ramos F, Ichim TE, Riordan NH.
Abstract
The medical significance of circulating endothelial or hematopoietic progenitors is becoming increasing recognized. While therapeutic augmentation of circulating progenitor cells using G-CSF has resulted in promising preclinical and early clinical data for several degenerative conditions, this approach is limited by cost and inability to perform chronic administration. Stem-Kine is a food supplement that was previously reported to augment circulating EPC in a pilot study. Here we report a trial in 18 healthy volunteers administered Stem-Kine twice daily for a 2 week period. Significant increases in circulating CD133 and CD34 cells were observed at days 1, 2, 7, and 14 subsequent to initiation of administration, which correlated with increased hematopoietic progenitors as detected by the HALO assay. Augmentation of EPC numbers in circulation was detected by KDR-1/CD34 staining and colony forming assays. These data suggest Stem-Kine supplementation may be useful as a stimulator of reparative processes associated with mobilization of hematopoietic and endothelial progenitors.
The Stem Cell Institute has integrated Intranasal MTF Therapy into its autism protocol:
MTF therapy features exosomes and over 300 beneficial molecules
Works in synergy with our stem cells
Offers anti-inflammatory and regenerative effects
Delivered in an easy-to-administer aerosol format via the nose
To discover more about MTF and its benefits, click here
We use cookies to ensure that we give you the best experience on our website. To find out more about cookies and how we use them on this site, see our privacy policy.AcceptPrivacy Policy